FDA MedWatch - Toprol-XL, Topamax, Tegretol, and Tegretol-XR: Re ports of medication errors

[Guest guest]

> >

> > FDA MedWatch - Toprol-XL, Topamax,

> Tegretol, and Tegretol-XR: Re

> > ports of medication errors

> >

> >

> >> MedWatch - The FDA Safety Information and Adverse

> Event Reporting Program

> >>

> >> AstraZeneca and FDA notified healthcare

> professionals reports of

> >> medication

> >> dispensing or prescribing errors between

> Toprol-XL (metoprolol succinate)

> >> extended release tablets, indicated for the

> treatment of hypertension,

> >> long-term treatment of angina pectoris, and heart

> failure NYHA Class II

> >> or

> >> III, and Topamax (topiramate), a product of

> Ortho-McNeil Neurologics,

> >> Inc,

> >> indicated for the treatment of epilepsy and

> migraine prophylaxis. There

> >> have

> >> also been reports of medication errors involving

> confusion between

> >> Toprol-XL

> >> and Tegretol or Tegretol-XR (carbamazepine),

> products of Novartis

> >> Pharmaceuticals Corporation, indicated for the

> treatment of complex

> >> partial

> >> seizures, generalized tonic-clonic seizures, and

> trigeminal neuralgia.

> >> These

> >> reports include instances where Toprol-XL was

> incorrectly administered to

> >> patients instead of Topamax, Tegretol, or

> Tegretol-XR, and vice versa,

> >> some

> >> of them leading to adverse events.

> >>

> >> Read the complete MedWatch 2005 Safety summary,

> including links to the

> >> Dear

> >> Healthcare Professional and Dear Pharmacist

> letters, at:

> >>

> >>

>

http://www.fda.gov/medwatch/safety/2005/safety05.htm#Toprol

> >>

> >> --------

> >>

> >> Thank you for using MedWatch as a trusted source

> for timely safety

> >> information on drugs and other medical products

> regulated by the U.S.

> >> Food and Drug Administration. If you find this

> e-mail notification

> >> helpful, please consider telling colleagues and

> friends about MedWatch.

> >> They can learn more about us and

> subscribe/unsubscribe to the e-list at

> >> the MedWatch homepage,

> http://www.fda.gov/medwatch or by going directly

> >> to

> http://list.nih.gov/cgi-bin/wa?SUBED1=medwatch & A=1

> >>

> >> This is an automated message delivery system --

> replying to this message

> >> will not reach MedWatch staff. If you have

> comments or questions about

> >> MedWatch or this e-mail, please contact us

> through our comments &

> >> feedback web page,

> http://www.fda.gov/medwatch/feedback.htm

> >>

> >

>

>

[Guest guest]

FDA MedWatch - Toprol-XL, Topamax, Tegretol, and Tegretol-XR: Re

ports of medication errors

> MedWatch - The FDA Safety Information and Adverse Event Reporting Program

>

> AstraZeneca and FDA notified healthcare professionals reports of

medication

> dispensing or prescribing errors between Toprol-XL (metoprolol succinate)

> extended release tablets, indicated for the treatment of hypertension,

> long-term treatment of angina pectoris, and heart failure NYHA Class II or

> III, and Topamax (topiramate), a product of Ortho-McNeil Neurologics, Inc,

> indicated for the treatment of epilepsy and migraine prophylaxis. There

have

> also been reports of medication errors involving confusion between

Toprol-XL

> and Tegretol or Tegretol-XR (carbamazepine), products of Novartis

> Pharmaceuticals Corporation, indicated for the treatment of complex

partial

> seizures, generalized tonic-clonic seizures, and trigeminal neuralgia.

These

> reports include instances where Toprol-XL was incorrectly administered to

> patients instead of Topamax, Tegretol, or Tegretol-XR, and vice versa,

some

> of them leading to adverse events.

>

> Read the complete MedWatch 2005 Safety summary, including links to the

Dear

> Healthcare Professional and Dear Pharmacist letters, at:

>

> http://www.fda.gov/medwatch/safety/2005/safety05.htm#Toprol

>

> --------

>

> Thank you for using MedWatch as a trusted source for timely safety

information on drugs and other medical products regulated by the U.S. Food

and Drug Administration. If you find this e-mail notification helpful,

please consider telling colleagues and friends about MedWatch. They can

learn more about us and subscribe/unsubscribe to the e-list at the MedWatch

homepage, http://www.fda.gov/medwatch or by going directly to

http://list.nih.gov/cgi-bin/wa?SUBED1=medwatch & A=1

>

> This is an automated message delivery system -- replying to this message

will not reach MedWatch staff. If you have comments or questions about

MedWatch or this e-mail, please contact us through our comments & feedback

web page, http://www.fda.gov/medwatch/feedback.htm